Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABARNANCE trial in borderline resectable pancreatic cancer
jRCTs031180319Phase 3Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic cancer (PC) comparing Gemcitabine + nab-paclitaxel with S-1 + concurrent radiotherapy (2 arms). Primary endpoints: R0 resection rate and Overall survival. Started Jun 2017; status: active, not recruiting.
02
Drugs
gemcitabinepaclitaxeltegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs031180319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180319.